Based on this first report of <i>BRAF</i> A598-T599insV mutation occurring in lung cancer, we discuss resistance mechanisms to ALK TKIs, implications of <i>BRAF</i> mutation in NSCLC, and <i>BRAF</i> A598-T599insV mutation in other cancers. This evidence concerns the gene ALK and non-small cell lung carcinoma.